Hormone Replacement Therapy Market Size & Share, by Replacement Therapy (Estrogen, Human Growth Hormone, Thyroid, Testosterone Replacement Therapy); Administration Route (Parenteral, Transdermal, Oral); Indication (Cancer, Growth Hormone Deficiency, Menopause, Male Hypothyroidism, Hypothyroidism) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2033

  • Report ID: 866
  • Published Date: Feb 09, 2023
  • Report Format: PDF, PPT

Companies Dominating the Hormone Replacement Therapy Landscape

top-features-companies
    • AbbVie Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Abbott Laboratories
    • Novo Nordisk A/S
    • Genentech, Inc.
    • Novartis AG
    • F. Hoffmann-La Roche Ltd
    • Merck KGaA
    • Mylan N.V.
    • Bayer AG
    • Eli Lilly and Company

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • Orion Pharma AB to acquire the clearance for darolutamide indication in the combination with docetaxel from U.S. Food and Drug Administration (FDA). The product is developed for the treatment of metastatic hormone-sensitive prostate cancer shortly known as (mHSPC).

  • Genentech, Inc. to release positive results from the Phase III SKYSCRAPER-01 study. The study was being conducted to monitor the anti-TIGIT immunotherapy tiragolumab plus Tecentriq (atezolizumab) vs Tecentriq alone as an initial (first-line) to find the cure for people living with advanced or metastatic non-small cell lung cancer (NSCLC).


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 866
  • Published Date: Feb 09, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Higher number of women hitting menopause and growing cases of anxiety disorders is estimated to majorly boost the market growth.

The market is anticipated to attain a CAGR of 8% over the forecast period, i.e., 2023-2033.

Possibilities of side-effects of the therapy and the requirement for higher initial investment are estimated to challenge the market growth.

The market in North America region is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.

The major players in the market are Abbott Laboratories, Novo Nordisk A/S, Genentech, Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Merck KGaA, Mylan N.V., Bayer AG, Eli Lilly and Company, and others.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue-generating capacity as well as the new products being launched into the market by the company.

The market is segmented by replacement therapy, administration route, indication, and by region.

The transdermal is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying